Navigation Links
Primary Graft Dysfunction Is Risk Factor For Lung Transplant Problem

Society for Heart and Lung Transplantation (ISHLT) definition. Those who did not have primary graft dysfunction immediately after transplantation were classified grade 0, while those with more severe graft dysfunction received a 1, 2 or 3.

In their analysis, the investigators found that all grades of primary graft dysfunction were associated with a significantly increased risk of BOS. Recipients with primary graft dysfunction grade 1 had the relative risk of 1.73; those with grade 2 had a relative risk of 2.13; and those with grade 3 were 2.53 times more likely to experience the later problem.

“This association has important clinical implications and suggests that the immunosuppressive regimen should be optimized and that lung function should be monitored closely for patients who develop primary graft dysfunction,” said Dr. Hachem.

The researchers noted that additional studies are needed to further investigate the molecular mechanisms of primary graft dysfunction and its relationship to BOS.

According to the ISHLT, this area of study is becoming increasingly important, as the number of lung transplants performed in the U.S. was a record 1,815 last year. They reported that survival was 78 percent at one year, 61 percent at three years, 49 percent at five years, and 25 percent at 10 years.

Source-Newswis
SRM
'"/>




Page: 1 2

Related medicine news :

1. Shortage Of Funds In Primary Care Trust In UK
2. What Will Primary Care Look Like In England by 2015?
3. Primary Health Care MoU Signed on the Sidelines of the PBD
4. Primary Care centers to provide out patient treatment
5. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
6. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
7. Gene That Causes Metastasis of the Primary Tumor, Identified
8. IMA To Train Doctors In Primary Treatment Of HIV/AIDS
9. Primary School Children Will Be Weighed And Parents Informed If They Are Obese
10. Funding Approved for Research into Primary Health Care
11. British Teachers Concerned About Primary School kid’s Sexual Behavio
Post Your Comments:
(Date:12/2/2008)...G, Mich., Dec. 2 Senior...nsurance companies gathered today to,oppose effor...ss legislation,through the lame duck session of t...f life or death for many of us in Michigan," said,...igan Disability Rights,Coalition. "A vote for thi...
(Date:12/2/2008)... Appointment of enterprise soft...celerate growth in revenue and subscribers of Yugm... Minneapolis, MN (PRWEB) December 2...rvice that lets people connect and collaborate ins...nt of Vas Bhandarkar as Chief Executive Officer. ,...
(Date:12/2/2008)...UMBUS, Ohio)Rare injuries accounted for 3.5 percen...007, according to the first study to examine rare ...es. Rare injuries include eye injuries, dental inj...and heat illness, which may result in high morbidi...ng consequences. , Football was associated with ...
(Date:12/2/2008)...T, Dec. 2 United America... owns and provides comprehensive healthcare,manag...ennessee, today,announced that its Board of Direc...horizing the Company to repurchase up to $1.0 mill... program allows for the Company,s common shares to...
Breaking Medicine News(10 mins):Health News:Opposition Continues to Grow to Blues' Legislation 2Health News:Opposition Continues to Grow to Blues' Legislation 3Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 2Health News:Yugma Appoints Vas Bhandarkar as Chief Executive Officer 3Health News:United American Healthcare Corporation Announces Stock Repurchase Program 2
...e. According to a recent study researchers find sm...eases the risk of having a baby with a cleft lip. ...d who were interviewed when their babies were abou...t the mother’s smoking habits before and during pr...
...the first step in the path for a treatment for hum...t time they have found a successful way to deliver... Gene therapy for muscular dystrophy has been a h...a delivery method for the whole body has been a ma...
... people infected with both HIV and hepatitis C hav...eir study, patients who are treated with a newer c...to rid their bodies of HCV than those who receive ...nt because as many as 300,000 of the estimated 1 m...
...may keep your blood pressure under control. Resear...who drank between 120 milliliters and 599 millilit...46-percent decreased risk of developing hypertensi...ople who consumed more than 600 milliliters a day ...
Other Medicine News:
(Date:12/1/2008)... ENB-0040 at Children,s Hospital, Health Sciences ...Newswire/ -- Enobia Pharma, an emerging Canadian b...utics for serious bone disorders, today announced ...ram for hypophosphatasia was dosed. Enobia is inve...B-0040 for the treatment of this rare and often cr...
(Date:12/1/2008)...cember 9 at 11:00 am ET to Discuss Phase 2 Study R...Calif., Dec. 1 Sunesis...rmaceutical company focused on the development and...oday announced new data from its studies of vorelo...ted during the 50th American Society of Hematology...
(Date:11/28/2008)...re/ -- German biotech company,Partec is expanding...ng and,AIDS patient follow-up diagnostics for dev... 2.5 million patient tests have been performed wit...low" system, supporting already,more than 1 milli...n of the,Partec innovation, the average cost of E...
(Date:11/26/2008)...ANKLIN, Mass., Nov. 26 P...ced today that it has received full approval from ...s U.S. pivotal trial to study the effectiveness of...ed therapy in the prevention of Contrast-Induced N... PLC,s request to expand their investigation from ...
Breaking Medicine Technology:Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for 2420 Million with New and Existing Institutional Investors 2134 1Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for 2420 Million with New and Existing Institutional Investors 2134 2Abdominal Fat Tied to High Risk for Coronary Trouble 8051 1Abdominal Fat Tied to High Risk for Coronary Trouble 8051 2Scientists seek to assess the microbial risks in the water we drink 8047 1Scientists seek to assess the microbial risks in the water we drink 8047 2Scientists seek to assess the microbial risks in the water we drink 8047 3Building blocks of life formed on Mars 1544 1Building blocks of life formed on Mars 1544 2
...east 45% additional,reduction in patients, LDL-cho...owering therapies, CARLSBAD, Calif., May 17, 2007 ...c. announced updated results from its ongoing,Phas... homozygous,familial hypercholesterolemia (HoFH), ...t the of Cardiology Annual Scientific Session,(ACC...
... Than for Asthma,Rheumatoid Arthritis and Migrain...y three out of,four ulcerative colitis (UC) suffer...rvey say not feeling well has become a normal part...ive when it comes,to their relationship with a spo...nt) and their emotional state (82 percent). , UC p...
Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 2Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 3Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 4Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 5Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 6Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 7Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 8Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life 9
Used for temporary internal drainage from the ureteropelvic junction to the bladder. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; C-Flex
Used for catheter or instrument introduction. The dual knobs allow the sheath to be peeled away and removed. The maximum diameter of the catheter or instrument to be introduced should be measured to
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use.
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: